Community-Acquired Infections
Conditions
Keywords
severe sepsis, toxic shock
Brief summary
The severe sepsis (SS) and toxic shock (TS) are both frequent and severe complications of infectious diseases. They are one of the top ten causes of death in industrialized countries. But an eventual protective role of beta-blockers (anti-hypertensive drug) in their occurrence on a community infection has never been studied. The objective of this study is to evaluate this role.
Detailed description
The severe sepsis (SS) and toxic shock (TS) are both frequent and severe complications of infectious diseases. They are one of the top ten causes of death in industrialized countries. The adrenergic system is heavily involved in this pathological/physiological context. If the effect of various therapeutic strategies allowing the care of the SS/TS was widely estimated, the impact, positive or negative, therapeutic prescribed in the long term or more punctually - but be that as it may before the arisen of the sepsis - on the evolution of a community acute infectious pathology towards the SS/TS, had only little studied. The main objective of this study is to estimate the possible protective role of a long-term prescription of a beta-blocker on the arisen of the SS/TS in patients having an acute infectious pathology of community origin. The secondary objective will be to estimate, at the patients having developed a SS/TS, the impact of this long-term prescription of beta-blockers on the mortality in intensive care unit (ICU).
Interventions
None listed
Sponsors
Rennes University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Common characteristics of cases and controls: * Patients aged of more than 18 years old * Hospitalized patients, during the period of study, via the ICU of the participating hospital center, for a community infectious pathology: * lower respiratory infections (pneumonia) * intra-abdominal infections (cholangitis, diverticulitis, peritonitis) * urinary parenchymal infection (pyelonephritis complicated or without abscess, prostatitis, orchitis, epididymitis) * infections of skin and soft tissue infections (cellulitis, fasciitis) * meningitis, endocarditis, osteo-articular infections, salpingitis Definition of cases: * Patient included in the study and admitted to the emergency service either directly from ICU or after a hospitalization in a specialty for severe sepsis or septic shock on their infectious disease community. Definition of controls: * Patient included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before being released from the hospital. Non inclusion Criteria: * Opposition of the patient to the IT processing of its data within the framework of this observational study. *
Exclusion criteria
Occurrence, during hospitalization, a severe sepsis or septic shock associated with a nosocomial superinfection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary outcome is the occurrence of severe sepsis, moving toward or away from septic shock. | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | From the date of randomization until the date of first documented assessed severe sepsis (moving toward or away from septic shock) up to the end of hospitalisation. |
Countries
France
Outcome results
None listed